Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025
Dynavax (Nasdaq: DVAX) will report third quarter 2025 financial results on Wednesday, November 5, 2025 after U.S. market close. The company will host a conference call and live audio webcast the same day at 4:30 p.m. ET / 1:30 p.m. PT. Investors can access the live webcast via the Investors > Events & Presentations page at https://investors.dynavax.com/events-presentations. A replay will be available for 30 days after the event. Participants must register to dial into the call and are advised to join about 10 minutes early. Contact information for investor/media inquiries is provided.
Business summary: Dynavax is a commercial-stage biopharmaceutical company with two commercial products: HEPLISAV-B vaccine and CpG 1018 adjuvant.
Dynavax (Nasdaq: DVAX) will report i risultati finanziari del terzo trimestre 2025 mercoledì 5 novembre 2025 dopo la chiusura del mercato statunitense. L'azienda terrà una conference call e una webcast audio dal vivo nello stesso giorno alle 16:30 ET / 13:30 PT. Gli investitori possono accedere al webcast in diretta tramite la pagina Investors > Events & Presentations all'indirizzo https://investors.dynavax.com/events-presentations. Una riproduzione sarà disponibile per 30 giorni dopo l'evento. I partecipanti devono registrarsi per accedere al collegamento telefonico e sono invitati ad accedere circa 10 minuti prima. Sono fornite informazioni di contatto per richieste di investitori/media.
Sommario aziendale: Dynavax è una società biofarmaceutica commerciale con due prodotti commerciali: vaccino HEPLISAV-B e adjuvante CpG 1018.
Dynavax (Nasdaq: DVAX) reportará los resultados financieros del tercer trimestre de 2025 el miércoles 5 de noviembre de 2025 después del cierre del mercado estadounidense. La compañía organizará una llamada de conferencia y transmisión en vivo en audio el mismo día a las 4:30 p.m. ET / 1:30 p.m. PT. Los inversores pueden acceder a la transmisión en vivo a través de la página Inversores > Eventos y Presentaciones en https://investors.dynavax.com/events-presentations. Habrá una repetición disponible durante 30 días después del evento. Los participantes deben registrarse para marcar al teléfono y se recomienda unirse aproximadamente 10 minutos antes. Se proporcionan datos de contacto para consultas de inversores/medios.
Resumen comercial: Dynavax es una empresa biofarmacéutica en fase comercial con dos productos comerciales: la vacuna HEPLISAV-B y el adyuvante CpG 1018.
Dynavax (나스닥: DVAX)은 2025년 3분기 재무 결과를 2025년 11월 5일 수요일 미국 시장 마감 후에 발표합니다. 회사는 같은 날 동일 시각 4:30 p.m. ET / 1:30 p.m. PT에 컨퍼런스 콜과 라이브 오디오 웹캐스트를 진행합니다. 투자자들은 https://investors.dynavax.com/events-presentations의 Investors > Events & Presentations 페이지를 통해 라이브 웹캐스트에 접속할 수 있습니다. 이벤트 후 30일간 재방송이 제공됩니다. 참가자는 전화 참여를 위해 등록해야 하며, 약 10분 일찍 참여하는 것이 좋습니다. 투자자/언론 문의 연락처가 제공됩니다.
기업 개요: Dynavax는 두 가지 상용 제품을 보유한 상용 단계 생물의약품 회사입니다: HEPLISAV-B 백신과 CpG 1018 보조제.
Dynavax (Nasdaq: DVAX) publiera les résultats financiers du troisième trimestre 2025 le mercredi 5 novembre 2025 après la fermeture du marché américain. L'entreprise organisera une conférence téléphonique et une diffusion audio en direct le même jour à 16h30 HE / 13h30 HP. Les investisseurs peuvent accéder à la diffusion en direct via la page Investors > Events & Presentations sur https://investors.dynavax.com/events-presentations. Une rediffusion sera disponible pendant 30 jours après l'événement. Les participants doivent s'inscrire pour composer le numéro et il leur est conseillé de se connecter environ 10 minutes avant. Les coordonnées pour les demandes des investisseurs/medias sont fournies. Résumé de l'entreprise : Dynavax est une société biopharmaceutique en phase commerciale avec deux produits commerciaux : le vaccin HEPLISAV-B et l'adjuvant CpG 1018.
Dynavax (Nasdaq: DVAX) wird die Finanzergebnisse des dritten Quartals 2025 am Mittwoch, dem 5. November 2025 nach US-Börsenschluss bekannt geben. Das Unternehmen wird am selben Tag eine Telefonkonferenz und einen Live-Audio-Webcast um 16:30 Uhr ET / 13:30 Uhr PT abhalten. Investoren können den Live-Webcast über die Seite Investors > Events & Presentations unter https://investors.dynavax.com/events-presentations abrufen. Eine Aufzeichnung wird 30 Tage nach der Veranstaltung verfügbar sein. Teilnehmer müssen sich registrieren, um sich in die Konferenz einzuwählen, und es wird empfohlen, etwa 10 Minuten früher beizutreten. Kontaktinformationen für Investoren-/Medienanfragen sind angegeben. Geschäftszusammenfassung: Dynavax ist ein kommerziell tätiges Biopharmaunternehmen mit zwei kommerziellen Produkten: den HEPLISAV-B Impfstoff und das CpG 1018 Adjuvans.
Dynavax (ناسداك: DVAX) ستُعلن عن نتائج الربع الثالث من عام 2025 في الأربعاء 5 نوفمبر 2025 بعد إغلاق السوق الأميركي. ستُعقد الشركة مكالمة هاتفية ومشاهدة بث صوتي مباشر في نفس اليوم عند الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة / 1:30 مساءً بتوقيت المحيط الهادئ. يمكن للمستثمرين الوصول إلى البث المباشر عبر صفحة Investors > Events & Presentations على https://investors.dynavax.com/events-presentations. سيكون هناك إعادة بث لمدة 30 يوماً بعد الحدث. يجب على المشاركين التسجيل للاتصال، وينصح بالانضمام قبل حوالي 10 دقائق. معلومات الاتصال لاستفسارات المستثمرين/وسائل الإعلام مرفقة. الملخص التجاري: Dynavax هي شركة بيولوجية دوائية في مرحلة تجارية مع منتجين تجاريين: لقاح HEPLISAV-B و adjuvant CpG 1018.
Dynavax（纳斯达克：DVAX） 将在 2025 年第三季度 财报公布时间于美股收盘后，于 2025 年 11 月 5 日，星期三 公布。公司将于同日举行电话会议并进行 实时音频网络广播，时间为 东部时间下午 4:30 / 太平洋时间下午 1:30。投资者可通过 https://investors.dynavax.com/events-presentations 的 Investors > Events & Presentations 页面访问实时网络广播。事件结束后将提供 30 天的重播。参与者必须注册才能拨入电话，建议提前大约 10 分钟 加入。提供给投资者/媒体查询的联系方式。业务概要：Dynavax 是一家处于商业阶段的生物制药公司，拥有两款商业产品：HEPLISAV-B 疫苗和 CpG 1018 佐剂。
- None.
- None.
Dynavax will host a conference call and live audio webcast on Wednesday, November 5, 2025, at 4:30 p.m. ET/1:30 p.m. PT.
The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.
To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the
For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-2025-financial-results-and-host-conference-call-on-november-5-2025-302591183.html
SOURCE Dynavax Technologies
FAQ
When will Dynavax (DVAX) report third quarter 2025 results?
What time is the Dynavax (DVAX) conference call and webcast on November 5, 2025?
How can investors access the Dynavax (DVAX) webcast for the Q3 2025 results?
Will there be a replay of the Dynavax (DVAX) Q3 2025 earnings webcast?
Do I need to register to join the Dynavax (DVAX) conference call on November 5, 2025?
Who are the investor contacts for Dynavax (DVAX) regarding the Q3 2025 call?
